Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors
Ronald Paquette, P. Nagesh Rao, Meenal Chalukya(University of California, Los Angeles), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), David Elashoff(University of California, Los Angeles), Elizabeth Spiteri(Stanford University), John Nicoll, Neil P. Shah(Unknown), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center)
Cited by 32
Related Papers
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|Cancer Cell|2002|1.6k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k